Edgewood Oncology Announces First Patient Dosed in Phase 1 Investigator-Sponsored Study of BTX-A51 in Liposarcoma
BROOKLINE, Mass.—October 6, 2024--Edgewood Oncology, a clinical-stage biotechnology company focused on delivering BTX-A51 to patients with hematologic malignancies and genetically-defined solid tumors, today announced that the first patient has been dosed in a Phase 1 investigator-sponsored study of BTX-A51 at Dana-Farber Cancer Institute. The trial is evaluating BTX-A51 in patients with metastatic and/or recurrent liposarcoma, which is characterized by Murine Double Minute Clone 2 (MDM2) amplifications.
BTX-A51 is a multi-specific kinase inhibitor targeting casein kinase 1 alpha (CK1α) and cyclin-dependent kinases 7 and 9 (CDK7 and CDK9)—key regulators of transcriptional control and tumor cell survival.
The ongoing Phase 1 study is a single-arm pilot trial designed to assess the safety and tolerability of BTX-A51, along with an initial evaluation of its biological activity in patients with advanced MDM2-amplified liposarcoma. The trial is currently open for enrollment. Additional details about the study can be found at clinicaltrials.gov under the identifier NCT06414434.
About Edgewood Oncology
Edgewood Oncology is a clinical-stage biotechnology company that was founded to deliver on the promise of BTX-A51 for patients with hematologic malignancies and genetically-defined solid tumors. BTX-A51 is an investigational, first-in-class, small molecule, multi-selective kinase inhibitor of CK1α, CDK7 and CDK9 that synergistically co-targets master regulators of cancer to activate programmed cell death, or apoptosis. BTX-A51 holds promise in acute myeloid leukemia and genetically-defined solid tumors, which are the focus of ongoing clinical programs. For more information, please visit www.edgewoodoncology.com, and follow us on LinkedIn.
Contact
Tracy Lessor
TLOW Communications, LLC
617-519-9827